GLP-3 RT

Weight Loss Peptide

GLP-3 RT

Retatrutide is a synthetic peptide studied for its interaction with GLP-1, GIP, and glucagon receptor pathways, making it a unique triple-pathway incretin compound in metabolic and endocrine research.

1
$79.99
Most Popular
Best Value
Est. delivery Jun 4 - Jun 8
Free shipment protection
Secure checkout
We accept: Visa Mastercard American Express
Free shipping on orders over $200
Damage protection on every order
Secure checkout 256-bit SSL
Certificate of Analysis
Tested for Identification, Purity, Mass, Endotoxins, Sterility, and Heavy Metals
LATEST SELECTED DOSAGE
99.56%
PURITY
Variant GLP-3 RT 10MG
Lot # RET-2601-A01
Labeled 10mg
Actual 10.62mg
Tested March 07, 2026
LATEST
99.38%
PURITY
Variant GLP-3 RT 20MG
Lot # RET-2601-A02
Labeled 20mg
Actual 19.52mg
Tested March 07, 2026
LATEST
99.63%
PURITY
Variant GLP-3 RT 30MG
Lot # RET-2601-A03
Labeled 30mg
Actual 32.95mg
Tested March 07, 2026
Compound Information
Pharmaceutical Specifications
Molecular Profile
What Is GLP-3 RT?
TypeSynthetic peptide
CAS Number2381928-69-2
Molecular FormulaC₂₂₄H₃₄₉N₄₇O₆₅
Molecular Weight4,765.54 g/mol
Amino Acids36
PubChem Database
Storage Requirements
Stability Information
Freeze for storage Refrigerate after reconstitution Protect from light
Lyophilized (powder)
-20°C  ·  24+ months
Reconstituted
2-8°C  ·  ~30 days
Research
Sources & References
CELL METABOLISM (CELL PRESS)
LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept
2022  ·  DOI: 10.1016/j.cmet.2022.07.013
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, et al.
View Source
THE LANCET
LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People with Type 2 Diabetes: A Phase 1b, Multicentre, Double-Blind, Placebo-Controlled, Randomised, Multiple-Ascending Dose Trial
2022  ·  DOI: 10.1016/S0140-6736(22)02033-5
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z
View Source
NEW ENGLAND JOURNAL OF MEDICINE
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023  ·  DOI: 10.1056/NEJMoa2301972
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML
View Source
THE LANCET
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
2023  ·  DOI: 10.1016/S0140-6736(23)01053-X
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T
View Source
NATURE MEDICINE
Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial
2024  ·  DOI: 10.1038/s41591-024-03018-2
Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, et al.
View Source
PROCEEDINGS OF BAYLOR UNIVERSITY MEDICAL CENTER (TAYLOR & FRANCIS)
Efficacy and Safety of Retatrutide, a Novel GLP-1, GIP, and Glucagon Receptor Agonist for Obesity Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2025  ·  DOI: 10.1080/08998280.2025.2456441
Abouelmagd AA, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM
View Source
BIOMOLECULES (MDPI)
Retatrutide — A Game Changer in Obesity Pharmacotherapy
2025  ·  DOI: 10.3390/biom15060796
Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K
View Source
CURRENT CARDIOVASCULAR RISK REPORTS (SPRINGER NATURE)
Triple Agonism Based Therapies for Obesity
2025  ·  DOI: 10.1007/s12170-025-00770-z
Patel N, le Roux CW, et al.
View Source

Weight Loss Peptide

Retatrutide is a synthetic peptide studied for its interaction with GLP-1, GIP, and glucagon receptor pathways, making it a unique triple-pathway incretin compound in metabolic and endocrine research.

Additional information

Quantity:

10MG, 20MG, 30MG

You May Also Like